This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

IMAAVY – Missed Dose in Patients with Generalized Myasthenia Gravis

Last Updated: 10/08/2025

Summary

  • The company cannot recommend any practices, procedures, or usage that deviate from the approved labeling.
  • Please refer to the local labeling for further information on dosage of IMAAVY.
  • If a scheduled infusion appointment is missed, the maintenance dose of IMAAVY should be administered as soon as possible. Resume dosing every two weeks thereafter.1 

 

References

1 Data on File. Nipocalimab Company Core Data Sheet v003. Janssen Research & Development, LLC. EDMS-RIM-1007434; 2025.